Miftahussurur Muhammad, Doohan Dalla, Syam Ari Fahrial, Nusi Iswan Abbas, Subsomwong Phawinee, Waskito Langgeng Agung, Maulahela Hasan, Akil Fardah, Uwan Willy Brodus, Siregar Gontar, Fauzia Kartika Afrida, Rezkitha Yudith Annisa Ayu, Rahman Abdul, Wibawa I Dewa Nyoman, Saudale Alexander Michael Joseph, Richardo Marselino, Sugihartono Titong, Chomariyati Alvi, Bramantoro Taufan, Uchida Tomohisa, Yamaoka Yoshio
Gastroentero-Hepatology Division, Department of Internal Medicine, Faculty of Medicine-Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya 60286, Indonesia.
Institute of Tropical Disease, Universitas Airlangga, Surabaya 60115, Indonesia.
Biology (Basel). 2021 Apr 6;10(4):300. doi: 10.3390/biology10040300.
polymorphisms are important factors for proton pump inhibitor-based therapy. We examined the genotypes and analyzed the distribution among ethnicities and clinical outcomes in Indonesia. We employed the polymerase chain reaction-restriction fragment length polymorphism method to determine the genotypes and evaluated inflammation severity with the updated Sydney system. For , 46.4% were the homozygous wild-type allele, 14.5% were the homozygous mutated allele, and 39.2% were the heterozygous allele. For , 88.6% were the homozygous wild-type allele, 2.4% were the homozygous mutated allele, and 9.0% were the heterozygous allele. Overall, the prevalence of rapid, intermediate, and poor metabolizers in Indonesia was 38.5, 41.6, and 19.9%, respectively. In the poor metabolizer group, the frequency of allele (78.8%) was higher than the frequency of allele (21.2%). The Papuan had a significantly higher likelihood of possessing poor metabolizers than the Balinese (OR 11.0; P = 0.002). The prevalence of poor metabolizers was lower compared with the rapid and intermediate metabolizers among patients with gastritis and gastroesophageal reflux disease. Intermediate metabolizers had the highest prevalence, followed by rapid metabolizers and poor metabolizers. Dosage adjustment should therefore be considered when administering proton pump inhibitor-based therapy in Indonesia.
基因多态性是基于质子泵抑制剂治疗的重要因素。我们在印度尼西亚研究了基因型，并分析了不同种族间的分布情况以及临床结局。我们采用聚合酶链反应-限制性片段长度多态性方法来确定基因型，并使用更新后的悉尼系统评估炎症严重程度。对于[具体基因1]，46.4%为纯合野生型等位基因，14.5%为纯合突变型等位基因，39.2%为杂合等位基因。对于[具体基因2]，88.6%为纯合野生型等位基因，2.4%为纯合突变型等位基因，9.0%为杂合等位基因。总体而言，印度尼西亚快速代谢者、中间代谢者和慢代谢者的患病率分别为38.5%、41.6%和19.9%。在慢代谢者组中，[等位基因1]的频率（78.8%）高于[等位基因2]的频率（21.2%）。巴布亚人拥有慢代谢者的可能性显著高于巴厘人（比值比11.0；P = 0.002）。在胃炎和胃食管反流病患者中，慢代谢者的患病率低于快速代谢者和中间代谢者。中间代谢者的患病率最高，其次是快速代谢者和慢代谢者。因此，在印度尼西亚进行基于质子泵抑制剂的治疗时应考虑剂量调整。
